The World Cancer Immunotherapy Conference is bringing together leading scientists and C-Level executives from across the globe to present research, case studies and viewpoints on various topics integral to a better understanding of the challenges and opportunities facing developers of therapeutic cancer vaccines. With the recent commercialization of Provenge, an approval path has now been mapped out, albeit with major challenges in terms of uptake and reimbursement. Moreover, with other novel vaccines nearing approval, now is the time to revisit the successes and failures of this development program as well as the challenges that still lie ahead. Topics and Themes Speakers and panelists at this conference will discuss the following: Cancer vaccine clinical trial design FDA guidance for cancer vaccine developers and regulatory challenges Biomarkers as an aid to clinical development of cancer vaccines Optimal disease settings for cancer vaccine intervention Cancer vaccines in combination therapies